Press Releases

Feb 22, 2010Ceragenix and BexPharm Enter Into Distribution and Supply Agreement for EpiCeram(R)
Jan 7, 2010Ceragenix and BioPro Enter into Distribution and Supply Agreement for EpiCeram(R)
Oct 26, 2009Second Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield(TM) Antimicrobial Coating Application
Sep 9, 2009NIH Issues $2.87 Million Grant for Development of Ceragenin(TM)-Based Drug to Treat Clostridium difficile and Shigella Gastrointestinal Infections
Sep 1, 2009Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield(TM) Antimicrobial Coating Application
Aug 13, 2009Ceragenix Completes Long-Term Antimicrobial Efficacy Test on Treated Silicone Medical Device
Jul 27, 2009Ceragenix and Megapharm Enter Into Distribution and Supply Agreement for EpiCeram(R)
Jul 9, 2009Ceragenix and Nobel Biocare Enter into Option to License Agreement for Antimicrobial Technology
Jun 22, 2009National Jewish Health and Ceragenix Announce Compound Shows Promise for Treating Potentially Lethal Viral Infections
May 19, 2009Ceragenix and Davi Enter Into Distribution and Supply Agreement for EpiCeram(R)
May 11, 2009Ceragenix Enters Into Second Exclusive Option to License Agreement for Antimicrobial Medical Device
May 4, 2009Ceragenix Achieves 200 Days of Antimicrobial Efficacy On Treated Silicone Medical Device
Apr 29, 2009Ceragenix and MAST BioSurgery Enter Into Joint Development Agreement for New Antimicrobial Surgical Products
Mar 30, 2009NIH Awards $1.66 Million Grant to Evaluate Cerashield Coating to Reduce Orthopedic Implant Infections
Feb 25, 2009Ceragenix and Pediapharm Enter Into Distribution and Supply Agreement for EpiCeram(R)
Feb 23, 2009Japanese Researchers Find CSA-13 May be Useful for Prevention and Treatment of Dental Caries and Periodontal Disease
Feb 3, 2009Ceragenix Achieves 120 Days of Antimicrobial Efficacy on Treated Silicone Medical Device
Feb 2, 2009Ceragenix and Hyphens Enter Into Distribution and Supply Agreement for EpiCeram
Oct 14, 2008Promius Pharma, LLC Launches EpiCeram(R) Skin Barrier Emulsion
Sep 22, 2008Ceragenix Satisfies Conditions for $1 Million Milestone Payment under Supply and Distribution Agreement
May 20, 2008Ceragenix Announces Results of a Comparison Study of the Safety and Efficacy of EpiCeram(R) Cream for the Treatment of Mild to Moderate Pediatric Atopic Dermatitis
Apr 29, 2008CeraShield(TM) Coated Urinary Catheters Provide Superior Protection Against Bacterial Colonization Compared to Leading Brands in Preclinical Testing
Apr 23, 2008Ceragenix to Present Urinary Catheter Data at European Conference
Apr 7, 2008Ceragenix Receives $1.5 Million Milestone Payment
Mar 25, 2008Ceragenix Enters into Agreement to License CSA-54 and other Ceragenin Compounds To Biopharmaceutical Company for HIV and STD Applications
Mar 13, 2008Ceragenix Completes Patient Visit Phase of Clinical Trial Study to Compare Efficacy of EpiCeram(R) to Elidel(R)
Jan 29, 2008Dr. Michael Niederman Joins Ceragenix Scientific Advisory Board
Dec 20, 2007Ceragenin(TM) Compound Demonstrates Potent Activity Against Multidrug Resistant Bacterial Strains of Pseudomonas
Nov 19, 2007Ceragenix and Dr. Reddy's Enter Into Distribution and Supply Agreement for EpiCeram(r)
Oct 31, 2007Ceragenix Pharmaceuticals to Present at The Rodman and Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
Oct 22, 2007Results of Pre-Clinical Investigation of Ceragenix's Developmental Antibiotic to Prevent Sepsis Presented at International Scientific Meeting
Sep 18, 2007Results of Pre-Clinical Investigations of Ceragenix's Developmental Antibiotic to Be Presented at International Scientific Meeting on Infectious Diseases
Aug 28, 2007Ceragenix Pharmaceuticals Receives Frost & Sullivan Product Innovation Award for Cerashield(TM) Coating
Aug 22, 2007Ceragenix Pharmaceuticals Provides Update on EpiCeram(R)
Jul 2, 2007Ceragenix(TM) Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
Jun 12, 2007FDA Grants Ceragenix's Request for Designation
May 8, 2007Ceragenix to Present at Rodman & Renshaw Global Healthcare Conference
Apr 25, 2007Ceragenix Commences Second in Series of Clinical Trials
Apr 24, 2007Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints
Apr 23, 2007Ceragenix Announces New Publication of Scientific Research on Ceragenin(TM) Technology
Mar 12, 2007Ceragenix Announces Ceragenins(TM) Virtually Prevent Catheter Biofilm Formation in 21 Day Study
Mar 8, 2007Ceragenix Announces Webcast on Use of Ceragenins(TM) as Antimicrobial Coating for Medical Devices and in Contact Lens Disinfectant Solutions
Mar 5, 2007Ceragenix Contact Lens Disinfectant Solution Demonstrates Potent Activity Against Bacteria and Fungi
Feb 26, 2007International Ophthalmology Conference to Feature Ceragenix's Anti-Microbial Technology
Feb 21, 2007Ceragenix Completes Patient Visits for EpiCeram(TM) Clinical Study
Jan 31, 2007Dr. Michael Rybak Joins Ceragenix's Scientific Advisory Board
Jan 17, 2007Ceragenix Provides Update on Clinical Study
Dec 11, 2006Ceragenix Completes $5 Million Financing
Sep 20, 2006Research on Ceragenins to Be Highlighted at Leading International Conference on Infectious Disease
Aug 14, 2006Ceragenix Pharmaceuticals Initiates EpiCeram(R) Clinical Trial; EpiCeram(R) to be Compared to Mid-Strength Steroid in Children with Moderate-to-Severe Eczema
Aug 3, 2006Ceragenix Pharmaceuticals Provides Mid-Year Update; Company Commencing Post-510k Clearance Studies for EpiCeram(R) to Support Current Partnering Discussions
Jul 31, 2006Research on Use of Ceragenins(TM) as Potential Therapy for Behcet's Disease to Be Presented at International Conference in Lisbon
Jul 26, 2006Research on Use of Ceragenins(TM) As Potential Therapy for Cystic Fibrosis Related Infections and Other Diseases to be Presented at ICAAC 2006
Jun 27, 2006Ceragenix Obtains IRB Approval for Eczema Clinical Study; Study to Compare EpiCeram(R) to Mid-Strength Topical Steroid in Treatment of Children with Moderate-to-Severe Eczema
Jun 21, 2006Ceragenix Enters Into Research and Development Agreement; Drugs Targeted Toward Prevention of Influenza Infection and Eradication of MRSA Bacterial Colonization
Jun 14, 2006FDA Grants Ceragenix's Request for Cerashield(TM) to be Reviewed as a Device; Ceragenix to Seek Expedited Review
Jun 12, 2006Ceragenix Compound Demonstrates Promising In Vitro Results Against Bladder Cancer
May 25, 2006Brigham Young University Named Winner in 2006 Utah Innovation Awards; Institution Recognized for CSA Research
May 18, 2006Ceragenix Compound Demonstrates Activity Against MRSA Biofilm
May 10, 2006Ceragenix Pharmaceuticals Enters Into Research Agreement With Johns Hopkins Burn Center to Evaluate Ceragenin Antimicrobial Wound Dressing
May 8, 2006Ceragenix Compound Demonstrates Activity Against MRSA Biofilm; Over 100 Fold Greater Effect in Eradicating MRSA Biofilm than Vancomycin
May 1, 2006Ceragenix to Present at Rodman & Renshaw Third Annual Global Healthcare Conference
Apr 12, 2006Ceragenix Receives 510k Clearance of EpiCeram(R) for the Treatment of Atopic Dermatitis and Other Skin Disorders
Apr 6, 2006Ceragenix Pharmaceuticals to Present at the BIO 2006 Business Forum
Mar 27, 2006Ceragenix Reports 2005 Year-End Financial Results and Business Progress
Mar 22, 2006Ceragenix Pharmaceuticals Provides Update on Company's Proprietary Compounds Tested by the National Cancer Institute; In-Vitro Data Show Anti-Angiogenenic Activity of Ceragenins
Feb 21, 2006Ceragenix Pharmaceuticals Appoints Dr. Donald Leung to its Scientific Advisory Board
Feb 8, 2006Centers for Disease Control and Prevention (CDC) and Ceragenix Enter into a Cooperative Research and Development Agreement (CRADA)
Feb 6, 2006Vanderbilt University, Brigham Young University, and Ceragenix Pharmaceuticals Report Novel Drug Compound Kills Multiple HIV Strains; Synthetic Small Molecule Acts Through Unique Strain-Independent Virucidal Mechanism
Dec 21, 2005In Vitro Study Results Show Ceragenix's Lead Antibiotic Compound Has Greater Bactericidal Activity against Potentially Lethal Bacterial Infections Than Leading Commonly-Prescribed Antibiotic Treatments
Dec 20, 2005Ceragenix Presents Positive Data on its Novel Antimicrobial Medical Device Coating at International Conference on Infectious Diseases
Dec 6, 2005Ceragenix Completes $3.2 Million Convertible Note Transaction
Nov 21, 2005Forum Alert: Ceragenix Pharmaceuticals, Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in San Francisco on Wednesday, December 7, 2005, 11:25 am PST
Oct 25, 2005Ceragenix Signs Letter of Intent with the Centers for Disease Control and Prevention (CDC) to Enter into a Cooperative Research and Development Agreement (CRADA)
Sep 26, 2005Ceragenix Submits 510(k) Application to FDA for Epiceram(TM), a Skin Barrier Cream for Treatment of Eczema and Other Skin Disorders
Sep 15, 2005Ceragenix Reports Results of Study of Its Epiceram (TM) Barrier Repair Cream; Study Demonstrates That Epiceram(TM) Accelerated Skin Barrier Recovery in Treated vs. Untreated Eczema Sites
Aug 24, 2005Webcast Alert: Ceragenix Pharmaceuticals, Inc. Presentation at Informed Investors Biotechnology, Healthcare, Pharmaceuticals Investor Forum to be Webcast on Thursday, August 25, 2005, 12:30 pm ET
Aug 17, 2005Ceragenix Pharmaceuticals' Chief Scientific Officer Awarded $1.2 Million Research Grant by National Institutes of Health
Aug 3, 2005Professor Richard Gallo, Leading Research Dermatologist, Joins Ceragenix's Scientific Advisory Board
Jul 22, 2005Professor Sean P. Gorman Joins Ceragenix Pharmaceuticals' Scientific Advisory Board; World Renowned Expert in Medical Device Coatings
Jul 19, 2005Results of Pre-Clinical Investigations of Ceragenix's Novel Antibiotic to Be Presented at Major International Scientific Meeting on Infectious Disease
Jul 7, 2005Ceragenix's Lead Compounds Show Anti-Angiogenic Activity; National Cancer Institute Accepts Compounds for Testing
Jun 28, 2005Ceragenix's New Antibiotic Has Potent Activity Against Vancomycin and Tobramycin Resistant Bacterial Infections
Jun 27, 2005OnSource Corporation Changes Name to Ceragenix Pharmaceuticals
Jun 24, 2005Antibiotic Resistant Bacteria A Major Health Threat to Worldwide Population
Jun 16, 2005Ceragenix Appoints Former President of Boston Scientific-Europe and Former President of Baxter Healthcare-Asia to Board of Directors
Jun 15, 2005Ceragenix Appoints Russell Allen Vice President of Corporate Development
May 23, 2005Ceragenix Pharmaceuticals to File 510k for Reformulation of Epiceram
May 11, 2005Osmotics Pharma, Inc. and OnSource Corporation Complete Merger